US FDA Cleared CLIA Waived Status for Neopharma Technologies NEOTEST
USFDA and CE
Neopharma Technologies (NEO) has received from the US FDA Cleared CLIA waived status for its NEOTEST Drug Test Multi Panel Cup and NEOTEST Drug Test Dip Card and CE certification for its full NEOTEST Drugs of Abuse (DOA) range including Cassette, Oral Fluid, Split Cup and Multi Cup. The CLIA waived status means that the NEOTEST Drug Test Multi Panel Cup and NEOTEST Drug Test Dip Cup can be marketed to the general public in the USA. It’s CE marking gives NEO the ability to sell the entire NEOTEST (DOA) range to the European market. All these rapid drug tests are empowered by NEOVAULT, an ISO 27001 certified IT platform.
NEOVAULT and Supporting Apps
NEOVAULT gives private companies and government organisations the ability to manage drug and alcohol as well as other health tests such as infectious disease. The NEOVAULT platform integrates seemlessly with two apps myNEO and the NEOVAULT app. The myNEO app is an end user app for the general public to easily follow test instructions, watch instructional videos and record and share health test results. The NEOVAULT app is a supervisor app to assist Medical Review Officers and Third Party Adminstrators to conduct rapid health tests and adminsister and record Drug Test Results for government and private organisations employees in ultimately managing a Safe Work Place.
Drug Test Devices
NEOTEST Drug Test Multi Panel Cup can test for upto 20 different Drugs and Alcohol.
NEOTEST Oral Fluid Can test upto 12 different Drugs and Alcohol.
NEOTEST Split Cup can test upto 7 different Drugs and Alcohol.
NEOTEST Dip Card can test upto 6 different Drugs and Alcohol.
NEOTEST Cassette can test upto 5 different Drugs and Alcohol.
List of Available Drugs for Detection
Acetaminophen (ACE), Amphetamine (AMP), Barbiturates (BAR), Barbiturates (BAR), Buprenorphine (BUP), Benzodiazepines (BZO), Cocaine (COC), Cotinine (COT), Clonazepam (CLO), MDMA (Ecstasy), Ethyl Glucuronide (ETG), Fentanyl (FEN), Gabapentin (GABA), Hydrocodone (HCD), Hydromorphone (HMO), K2 Synthetic Cannabinoid, K3 (AB-Pinaca), Ketamine (KET), Kratom (KRA), Lysergic acid diethylamide (LSD), Marijuana (THC), EDDP (Methadone Metabolites), Methadone (MTD), Methamphetamine (MET, mAMP ), Methaqualone (MQL), Methcathinone (MTC), Methylenedioxypyrovalerone (MDPV), Methylphenidate (MPD), 6 Monoacetylmorphine (6-MAM), Morphine (MOP), Oxycodone (OXY), Phencyclidine (PCP), Pregabalin (PGB), Propoxyphene (PPX), UR-144, Carisoprodol (SOMA), Tramadol (TRA), Tricyclic Antidepressants (TCA), Alcohol (ALC).
Shaun Melville Executive Director NEO said “We are excited to enter this next phase of the business to deliver the highest quality rapid test kits and utilise our technologies to add value for consumers and governments throughout the USA and Europe”.
About Neopharma Technologies Ltd (NEO)
Neopharma Technologies is a public unlisted Australian Company with wholly owned subsidiaries in Malaysia and the USA. Neopharma Technologies is positioning itself to be a global leader for Safe Workplace Best Practice rapid testing in the global workplace. It is a proud member of the NDASA (National Drug & Alcohol Screening Association).
For more information visit: https://neopharmatechnologies.com
Media Contact
Company Name: Neopharma Technologies Ltd (NEO)
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://neopharmatechnologies.com
